LumiraDx Receives FDA EUA for the LumiraDx SARS-CoV-2 Antigen Test

LumiraDx SARS-CoV-2 antigen test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application in symptomatic patients. In clinical studies, the LumiraDx SARS-CoV-2 antigen test demonstrated 97.6% positive agreement versus PCR in patients tested within 12 days of the onset of symptoms, making it the fastest, most sensitive antigen point of care test currently commercially available.

LumiraDx and Chembio announce COVID-19 Strategic Partnership

The agreement builds on the strengths of both companies in delivering novel point of care test solutions.